Progression of Mycosis Fungoides After Fingolimod Treatment for Multiple Sclerosis and Targeted Next-Generation Sequencing Demonstrating Potential Links Between the Two Diseases

JCO Precis Oncol. 2023 Feb:7:e2200501. doi: 10.1200/PO.22.00501.

Authors

Saisindhu Narala^{1

2}, Yonglu Che², Atif Saleem¹, Christopher B Lock³, Youn H Kim², Kerri E Rieger^{1

2}

Affiliations

¹ Department of Pathology, Stanford University School of Medicine, Stanford, CA.
² Department of Dermatology, Stanford University School of Medicine, Stanford, CA.
³ Division of Neuroimmunology, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA.

PMID: 36724412
DOI: 10.1200/PO.22.00501

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Fingolimod Hydrochloride / adverse effects
High-Throughput Nucleotide Sequencing
Humans
Multiple Sclerosis* / drug therapy
Multiple Sclerosis* / genetics
Mycosis Fungoides* / drug therapy
Mycosis Fungoides* / genetics
Skin Neoplasms* / drug therapy
Skin Neoplasms* / genetics

Substances

Fingolimod Hydrochloride